American Diversifield Holdings Corporation (ADHC) Provides Update on Dexcom/GlucoGuard App Development Through UC Irvine MADO Program
American Diversified Holdings (ADHC) has provided an update on its GlucoGuard app development through the University of California, Irvine's Make A Difference Opportunity (MADO) Program. During Spring 2024, the team achieved key milestones including developing a functional front-end and back-end system, training a predictive algorithm with 95% accuracy for hypoglycemic detection, and securing Registered Developer access to Dexcom API.
For Spring 2025, GlucoGuard aims to advance development to enable mobile device functionality and upgrade to Access Dexcom API for real-time blood glucose monitoring from G6 and G7 devices. The software development through UCI MADO program runs parallel to hardware development, strengthening IP claims, supporting regulatory approval, and optimizing R&D timelines.
The GlucoGuard system, being developed with three key partners including a U.S. research university, a biomedical engineering firm, and a public CGM company, combines AI and mobile monitoring to manage nocturnal hypoglycemia through an automated glucose-administering mouthpiece.
American Diversified Holdings (ADHC) ha fornito un aggiornamento sullo sviluppo della sua app GlucoGuard attraverso il programma Make A Difference Opportunity (MADO) dell'Università della California, Irvine. Durante la primavera del 2024, il team ha raggiunto traguardi importanti, tra cui lo sviluppo di un sistema funzionale front-end e back-end, l'addestramento di un algoritmo predittivo con il 95% di precisione per la rilevazione dell'ipoglicemia e l'ottenimento dell'accesso come Sviluppatore Registrato all'API di Dexcom.
Per la primavera del 2025, GlucoGuard punta a progredire nello sviluppo per abilitare la funzionalità sui dispositivi mobili e aggiornare l'accesso all'API di Dexcom per il monitoraggio in tempo reale della glicemia da dispositivi G6 e G7. Lo sviluppo software attraverso il programma UCI MADO procede parallelamente allo sviluppo hardware, rafforzando le rivendicazioni di proprietà intellettuale, supportando l'approvazione normativa e ottimizzando i cronoprogrammi di R&S.
Il sistema GlucoGuard, in fase di sviluppo con tre partner chiave tra cui un'università di ricerca degli Stati Uniti, un'azienda di ingegneria biomedica e un'azienda pubblica di CGM, combina AI e monitoraggio mobile per gestire l'ipoglicemia notturna tramite un bocchino automatizzato per la somministrazione dell glucosio.
American Diversified Holdings (ADHC) ha proporcionado una actualización sobre el desarrollo de su aplicación GlucoGuard a través del programa Make A Difference Opportunity (MADO) de la Universidad de California, Irvine. Durante la primavera de 2024, el equipo logró hitos clave, incluyendo el desarrollo de un sistema funcional de front-end y back-end, el entrenamiento de un algoritmo predictivo con un 95% de precisión para la detección de hipoglucemia, y la obtención de acceso como Desarrollador Registrado a la API de Dexcom.
Para la primavera de 2025, GlucoGuard tiene como objetivo avanzar en el desarrollo para habilitar la funcionalidad en dispositivos móviles y actualizar el acceso a la API de Dexcom para el monitoreo en tiempo real de la glucosa en sangre desde dispositivos G6 y G7. El desarrollo de software a través del programa UCI MADO se lleva a cabo en paralelo con el desarrollo de hardware, fortaleciendo las reclamaciones de propiedad intelectual, apoyando la aprobación regulatoria y optimizando los plazos de I+D.
El sistema GlucoGuard, que se desarrolla con tres socios clave, que incluyen una universidad de investigación de EE. UU., una empresa de ingeniería biomédica y una empresa pública de CGM, combina inteligencia artificial y monitoreo móvil para gestionar la hipoglucemia nocturna a través de una boquilla automatizada para la administración de glucosa.
American Diversified Holdings (ADHC)는 캘리포니아 대학교 어바인의 'Make A Difference Opportunity (MADO)' 프로그램을 통해 GlucoGuard 앱 개발에 대한 업데이트를 제공했습니다. 2024년 봄 동안 팀은 기능적인 프론트엔드와 백엔드 시스템을 개발하고, 95%의 정확도로 저혈당 감지를 위한 예측 알고리즘을 훈련하며, Dexcom API에 대한 등록 개발자 접근 권한을 확보하는 등의 주요 이정표를 달성했습니다.
2025년 봄을 위해 GlucoGuard는 모바일 기기 기능을 활성화하고 G6 및 G7 장치에서 실시간 혈당 모니터링을 위한 Dexcom API에 대한 접근 권한을 업그레이드하는 개발을 진행할 계획입니다. UCI MADO 프로그램을 통한 소프트웨어 개발은 하드웨어 개발과 병행되며, 지적 재산의 주장을 강화하고 규제 승인을 지원하며 연구 개발 일정을 최적화합니다.
GlucoGuard 시스템은 미국의 연구 대학, 생의학 공학 회사 및 공공 CGM 회사와 함께 세 명의 주요 파트너와 협력하여 개발되며, AI와 모바일 모니터링을 결합하여 자동화된 글루코스 투여 마우스피스를 통해 야간 저혈당을 관리합니다.
American Diversified Holdings (ADHC) a fourni une mise à jour sur le développement de son application GlucoGuard via le programme Make A Difference Opportunity (MADO) de l'Université de Californie, Irvine. Au printemps 2024, l'équipe a atteint des étapes clés, notamment le développement d'un système fonctionnel de front-end et de back-end, l'entraînement d'un algorithme prédictif avec 95 % de précision pour la détection de l'hypoglycémie, et l'obtention d'un accès en tant que Développeur Enregistré à l'API de Dexcom.
Pour le printemps 2025, GlucoGuard vise à faire avancer le développement pour permettre la fonctionnalité sur les appareils mobiles et à mettre à jour l'accès à l'API de Dexcom pour le suivi en temps réel de la glycémie à partir des dispositifs G6 et G7. Le développement logiciel via le programme UCI MADO se déroule parallèlement au développement matériel, renforçant les revendications de propriété intellectuelle, soutenant l'approbation réglementaire et optimisant les délais de R&D.
Le système GlucoGuard, en cours de développement avec trois partenaires clés, dont une université de recherche américaine, une entreprise d'ingénierie biomédicale et une entreprise publique de CGM, combine l'IA et la surveillance mobile pour gérer l'hypoglycémie nocturne à l'aide d'un embout buccal automatisé pour l'administration de glucose.
American Diversified Holdings (ADHC) hat ein Update zur Entwicklung seiner GlucoGuard-App durch das Make A Difference Opportunity (MADO) Programm der University of California, Irvine bereitgestellt. Im Frühling 2024 erreichte das Team wichtige Meilensteine, darunter die Entwicklung eines funktionalen Frontend- und Backend-Systems, das Training eines prädiktiven Algorithmus mit 95% Genauigkeit zur Erkennung von Hypoglykämie und den Erhalt des Zugangs als registrierter Entwickler zur Dexcom API.
Für den Frühling 2025 plant GlucoGuard, die Entwicklung voranzutreiben, um die Funktionalität mobiler Geräte zu ermöglichen und den Zugriff auf die Dexcom API für die Echtzeit-Blutzuckermessung von G6- und G7-Geräten zu aktualisieren. Die Softwareentwicklung über das UCI MADO-Programm verläuft parallel zur Hardwareentwicklung, stärkt die IP-Ansprüche, unterstützt die behördliche Genehmigung und optimiert die F&E-Zeitpläne.
Das GlucoGuard-System, das mit drei wichtigen Partnern, darunter einer US-Forschungshochschule, einem biomedizinischen Ingenieurbüro und einem öffentlichen CGM-Unternehmen, entwickelt wird, kombiniert KI und mobiles Monitoring, um nächtliche Hypoglykämie durch ein automatisiertes Glukoseabgabemundstück zu verwalten.
- Achieved 95% accuracy in hypoglycemic episode prediction algorithm
- Secured Dexcom API access for CGM data integration
- Parallel software development reduces overall R&D costs
- Established partnerships with three major industry players
- Hardware development still pending capital securing
- Access to Dexcom API not yet obtained
Del Mar, California--(Newsfile Corp. - February 4, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) pleased to provide the shareholder community an update on the progress Glucoguard has made in the development of the app through our engagement with the University of California, Irvine's Make A Difference Opportunity (MADO) Program.
In the Spring 2024 semester, Glucoguard was invited to participate in the MADO program through our ongoing relationship with the UCI administration. The program connects undergraduate and graduate students with local businesses, offering them hands-on experience working on real-world projects.
During our initial engagement in the program, the team achieved several key milestones:
- Developed a functional front-end and back-end capable of running on an emulator.
- Trained a predictive algorithm for detecting hypoglycemic episodes with
95% accuracy. - Secured Registered Developer access to the Dexcom API, enabling initial integration with continuous glucose monitoring (CGM) data.
Building on this success, Glucoguard has committed to participating in the Spring 2025 round of the program. The primary objectives for this next phase include:
- Advancing the front-end and back-end development to the point where the app can be loaded and run on a mobile device.
- Upgrading to Limited Access to the Dexcom API, allowing real-time access and analysis of blood glucose values from the Dexcom G6 and G7 Continuous Glucose Monitors.
Achieving these goals will result in a fully functional mobile app capable of integrating with CGM data-an essential component of the GlucoGuard device, which requires both hardware and software development. The ability to leverage the UCI MADO program for software development is a significant advantage, as it enables IMD to advance key technical components ahead of hardware development.
Having a working app will also play a crucial role in several strategic areas:
- Intellectual Property & Patent Prosecution- A developed app strengthens IP claims by providing tangible evidence of functionality.
- Investor & Regulatory Engagement - Developing the app will serve as a key tool in showcasing the value proposition of the GlucoGuard device to analysts by providing a tangible demonstration of its functionality and potential impact. Additionally, having a fully operational app will help regulatory agencies better understand how the device integrates with continuous glucose monitoring technology, supporting a clearer and more compelling case for approval.
- Streamlining Product Development - Completing the software component in parallel with hardware development will help optimize the R&D timeline and reduce overall development costs.
As ADHC secures the capital necessary to initiate hardware development, we look forward to sharing further updates as we progress through the next phase of the program.
COMPANY OVERVIEW
Key Development Partnerships
The GlucoGuard system is being developed in collaboration with three key partners:
- A leading U.S. research university.
- A highly respected biomedical and defense engineering firm.
- A top publicly traded company in the Continuous Glucose Monitoring (CGM) sector.
Further details on these collaborations will be disclosed soon.
Cutting-Edge Technology for Unmet Medical Needs
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest.
About Artificial Intelligence and Health Care
A recent report from the Mayo Clinic identified three potential benefits of AI in healthcare:
- Improving outcomes for both patients and clinical teams.
- Lowering healthcare costs.
- Benefitting population health.
From preventive screenings to diagnosis and treatment, AI is being used throughout the continuum of care today. Two examples are Preventive Health Care and Risk Assessment.
Cancer Screenings that use radiology can leverage AI to help produce results faster. A noted example is analyzing kidney images in a laborious 45 minute process. AI automated process can reduce this analysis to minutes, saving time, money and giving a more accurate diagnosis.
Pre-diabetes patients with no notable symptoms can be screened using AI to determine which type of diabetes they are at risk for and begin preventative care.
See AI in healthcare: The future of patient care and health management - Mayo Clinic Press.
About the Diabetes Market
The diabetes market is poised for substantial growth, with the U.S. market valued at
For more information on the
The Continuous Glucose Monitoring (CGM) sector, valued at
For details on the CGM market, visit: Continuous Glucose Monitoring Market.
Image 1
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/239485_457ac75f743d3a7e_001full.jpg
About IMD Solutions, Inc.
IMD Solutions, Inc. is a Nevada-based medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, IMD Solutions is at the forefront of diabetes management technology.
For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
Email: info@GlucoGuardSleep.com
Image 2
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/239485_457ac75f743d3a7e_002full.jpg
About AMERICAN DIVERSIFIED HOLDINGS CORPORATION
www.UniversalWellnessAI.com
www.UniversalWellnessShop.com
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com
Social Media:
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.
SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239485
FAQ
What accuracy rate did ADHC's GlucoGuard achieve in detecting hypoglycemic episodes?
When will ADHC's GlucoGuard app be ready for mobile device deployment?
What are the key partnerships for ADHC's GlucoGuard development?
How does ADHC's GlucoGuard system manage nocturnal hypoglycemia?
What is ADHC's current status with Dexcom API integration?
